Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-PSMA CAR-NK cells (CIH-CAMS)
- Development stage
- Phase 1
- Lead developer
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
This is an experimental allogeneic chimeric antigen receptor (CAR) natural killer (NK) cell therapy targeting prostate-specific membrane antigen (PSMA). Developed by the Cancer Institute and Hospital, Chinese Academy of Medical Sciences, it is designed for the treatment of metastatic castration-resistant prostate cancer (mCRPC). The therapy involves genetically modifying NK cells to express CARs that specifically recognize PSMA, a protein highly expressed on the surface of prostate cancer cells. This engineering allows the NK cells to precisely target and eliminate tumor cells while potentially offering a better safety profile compared to CAR-T cell therapies. It is currently being evaluated in an early phase 1 clinical trial to assess safety, tolerability, and preliminary efficacy in patients who have exhausted standard treatment options.
- Other names
- allogeneic anti-PSMA CAR-NK cellsanti-prostate-specific membrane antigen chimeric antigen receptor natural killer cells
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on anti-PSMA CAR-NK cells (CIH-CAMS).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-PSMA CAR-NK cells (CIH-CAMS).